Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | MVD | P53602 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | PPARD | Q03181 | 4/20 | 0.36 |
| ▸ | PPARA | Q07869 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31305127 | 0.96 | FFAR3 (0.44) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL6936379 | 0.86 | ALDH1A1 (0.58) | ALDH1A1EPHX2AKR1B1PPARGPPARD | |
| SCHEMBL6938138 | 0.85 | EPHX2 (0.54) | ALDH1A1EPHX2PHF8AKR1B1PPARG | |
| SCHEMBL2904687 | 0.83 | EPHX2 (0.57) | ALDH1A1EPHX2PHF8AKR1B1PPARG | |
| SCHEMBL2852602 | 0.83 | EPHX2 (0.57) | ALDH1A1EPHX2PHF8AKR1B1PPARG | |
| SCHEMBL25183153 | 0.83 | EPHX2 (0.57) | ALDH1A1EPHX2PHF8AKR1B1PPARG | |
| SCHEMBL8776565 | 0.83 | EPHX2 (0.57) | ALDH1A1EPHX2PHF8AKR1B1PPARG | |
| SCHEMBL3997562 | 0.83 | EPHX2 (0.57) | ALDH1A1EPHX2PHF8AKR1B1PPARG | |
| SCHEMBL4396598 | 0.83 | EPHX2 (0.57) | ALDH1A1EPHX2PHF8AKR1B1PPARG | |
| SCHEMBL219261 | 0.83 | EPHX2 (0.57) | ALDH1A1EPHX2PHF8AKR1B1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513413-A1 | PLASTICIZED PROLAMINE COMPOSITIONS | WM. WRIGLEY JR. COMPANY (US) | 2005-03-16 | — | — | EP | claimed |
| US-6733578-B2 | Plasticized prolamine compositions | WM. WRIGLEY JR. COMPANY | 2004-05-11 | — | — | US | claimed |
| WO-2004000030-A1 | PLASTICIZED PROLAMINE COMPOSITIONS | WM. WRIGLEY JR. COMPANY (US) | 2003-12-31 | — | — | WO | claimed |
| US-20030235639-A1 | Plasticized prolamine compositions | WM. WRIGLEY JR. COMPANY | 2003-12-25 | — | — | US | claimed |
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-01-02 | — | — | US | disclosed |
| EP-4433093-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-09-25 | — | — | EP | disclosed |
| CN-118488855-A | Solid composition comprising peptide or protein and acylated amino acid | 阿道恰公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4299057-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-01-03 | — | — | EP | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023084118-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2023-05-19 | — | — | WO | disclosed |
| EP-4180060-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2023-05-17 | — | — | EP | disclosed |
| US-20210069268-A1 | METABOLOMIC REVISION OF MAMMALIAN INFANTS | Evolve Biosystems, Inc. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2012075494-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012021796-A2 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012009715-A2 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| EP-1513413-A1 | PLASTICIZED PROLAMINE COMPOSITIONS | WM. WRIGLEY JR. COMPANY (US) | 2005-03-16 | — | — | EP | disclosed |
| US-6733578-B2 | Plasticized prolamine compositions | WM. WRIGLEY JR. COMPANY | 2004-05-11 | — | — | US | disclosed |
| WO-2004000030-A1 | PLASTICIZED PROLAMINE COMPOSITIONS | WM. WRIGLEY JR. COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030235639-A1 | Plasticized prolamine compositions | WM. WRIGLEY JR. COMPANY | 2003-12-25 | — | — | US | disclosed |
| US-5358946-A | Heterocycle-substituted amides, carbamates and ureas as agents for the treatment of atherosclerosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPPA, BCAT1, ANPEP | FFAR3 1090/4885HDAC3 752/4885HDAC1 782/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | FFAR3 1191/4885HDAC3 2994/4885HDAC1 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.